Jazz Pharmaceuticals plc reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported revenue was USD 1,126.11 million compared to USD 1,054.97 million a year ago. Net income was USD 251.41 million compared to USD 215.06 million a year ago. Basic earnings per share from continuing operations was USD 4.14 compared to USD 3.5 a year ago. Diluted earnings per share from continuing operations was USD 4.08 compared to USD 3.42 a year ago.
For the nine months, revenue was USD 3,069.66 million compared to USD 2,980.78 million a year ago. Net loss was USD 559.6 million compared to net income of USD 369.01 million a year ago. Basic loss per share from continuing operations was USD 9.18 compared to basic earnings per share from continuing operations of USD 5.93 a year ago. Diluted loss per share from continuing operations was USD 9.18 compared to diluted earnings per share from continuing operations of USD 5.63 a year ago.
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Companyâs lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
